Volume 9, Issue 6, Pages (June 2006)

Slides:

Advertisements

Similar presentations

Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression María J. Bueno, Ignacio Pérez de Castro, Marta Gómez de.

Advertisements

Origins of Metastatic Traits Sakari Vanharanta, Joan Massagué Cancer Cell Volume 24, Issue 4, Pages (October 2013) DOI: /j.ccr

Maintaining Cell Identity through Global Control of Genomic Organization Gioacchino Natoli Immunity Volume 33, Issue 1, Pages (July 2010) DOI: /j.immuni

Evolution of the Cancer Stem Cell Model Antonija Kreso, John E. Dick Cell Stem Cell Volume 14, Issue 3, Pages (March 2014) DOI: /j.stem

Nuclear Receptors, RXR, and the Big Bang Ronald M. Evans, David J. Mangelsdorf Cell Volume 157, Issue 1, Pages (March 2014) DOI: /j.cell

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell Volume.

Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia Tim C.P. Somervaille, Michael L. Cleary Cancer Cell.

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity Cai-Hong.

Tumor Entrained Neutrophils Inhibit Seeding in the Premetastatic Lung Zvi Granot, Erik Henke, Elizabeth A. Comen, Tari A. King, Larry Norton, Robert Benezra.

Shaping Genetic Alterations in Human Cancer: The p53 Mutation Paradigm Thierry Soussi, Klas G. Wiman Cancer Cell Volume 12, Issue 4, Pages (October.

A Conditional Mouse Model of Synovial Sarcoma: Insights into a Myogenic Origin Malay Haldar, Jeffrey D. Hancock, Cheryl M. Coffin, Stephen L. Lessnick,

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Fig. 2. High-resolution melting curves for exon 21 of the EGFR gene

Steroid-related emphysematous cystitis in an EGFR-mutant patient with lung adenocarcinoma while on gefitinib treatment Diego Marquez-Medina, Sanjay Popat

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

New Views into the Prostate Cancer Genome

Cancer: Inappropriate Expression of Stem Cell Programs?

Building better therapy for children with acute lymphoblastic leukemia

We Contain Multitudes: The Protean Face of Retinoblastoma

“Atypical” Regulation of Hedgehog-Dependent Cancers

Linking miRNA Regulation to BCR-ABL Expression: The Next Dimension

Carlos L. Arteaga, Jeffrey A. Engelman Cancer Cell

Metastasis gets site specific

Jens T. Siveke, Roland M. Schmid Cancer Cell

Accelerating drug discovery: Open source cancer cell biology?

Three Down and One To Go: Modeling Medulloblastoma Subgroups

A Sweet New Role for EGFR in Cancer

Renée van Amerongen, Anton Berns Cancer Cell

Cross-Species Oncogenomics in Cancer Gene Identification

MDS Is a Stem Cell Disorder After All

DAISY: Picking Synthetic Lethals from Cancer Genomes

Volume 26, Issue 1, Pages 1-2 (July 2014)

Eun-Jung Jung, George A. Calin Cancer Cell

The Wind God Promotes Lung Cancer

A Radical Role for p38 MAPK in Tumor Initiation

The AML Salad Bowl Cancer Cell

Volume 9, Issue 6, Pages (June 2006)

Association of Epidermal Growth Factor Receptor Activating Mutations with Low ERCC1 Gene Expression in Non-small Cell Lung Cancer David R. Gandara, MD,

Squamous-cell transformation in a patient with lung adenocarcinoma receiving erlotinib: Co-occurrence with T790M mutation Diogo D.G. Bugano, Neda Kalhor,

Hopping between Differentiation States in Lung Adenocarcinoma

Tetsuya Mitsudomi, MD, Hirohito Tada, MD Journal of Thoracic Oncology

The p27Kip1 tumor suppressor gene: Still a suspect or proven guilty?

Volume 9, Issue 6, Pages (June 2006)

Lung Cancer: A Wily Genetic Opponent

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations Benjamin Haaland, PhD, Pui San Tan,

Modeling the cancer patient with genetically engineered mice

Modifying Mitochondrial tRNAs: Delivering What the Cell Needs

Geographic Variation in EGFR Mutation Frequency in Lung Adenocarcinoma May Be Explained by Interethnic Genetic Variation Lars Soraas, MSc, Justin Stebbing,

Considering the critical interface between tumor cells and stromal cells in the search for targets for anticancer therapy Laurence Blavier, Yves A. DeClerck

Lung Cancer Resets the Liver’s Metabolic Clock

Volume 22, Issue 3, Pages (September 2012)

Mapping Cancer Origins

Do Complex Mutations of the Epidermal Growth Factor Receptor Gene Reflect Intratumoral Heterogeneity? Akito Hata, MD, Shiro Fujita, MD, PhD, Reiko Kaji,

Erratum Journal of Thoracic Oncology

Bmi1 and Cell of Origin Determinants of Brain Tumor Phenotype

Drugging Drug Resistance

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

EGFR delE709_T710insD: A Rare but Potentially EGFR Inhibitor Responsive Mutation in Non–Small-Cell Lung Cancer Allison Ackerman, MD, Michael A. Goldstein,

Volume 14, Issue 4, Pages (October 2008)

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

Autocrine IL-6 Signaling: A Key Event in Tumorigenesis?

Tumor Oncogenotypes and Lung Cancer Stem Cell Identity

Tyrosine kinase inhibitors

To Infinium, and Beyond! Cancer Cell

Volume 10, Issue 3, Pages (September 2006)

There's a Time and a Place for MYCN

Ibrutinib Treatment of CLL: The Cancer Fights Back

Volume 12, Issue 6, Pages (December 2007)

The AML Salad Bowl Cancer Cell

Presentation transcript:

Volume 9, Issue 6, Pages 421-423 (June 2006) EGF receptor mutations in lung cancer: From humans to mice and maybe back to humans Carlos L. Arteaga Cancer Cell Volume 9, Issue 6, Pages 421-423 (June 2006) DOI: 10.1016/j.ccr.2006.05.014 Copyright © 2006 Elsevier Inc. Terms and Conditions

Figure 1 Transgenic mice expressing L858R/EGFR and Del/EGFR develop bronchioloalveolar cancer and lung adenocarcinoma These histological types of tumors are identical to those observed in patients with NSCLC harboring these same receptor mutants. Mouse lung tumors responded dramatically to treatment with erlotinib, HKI-272, or cetuximab. Clinical activity of HKI-272 and cetuximab against human NSCLC expressing EGFR mutations remains to be formally tested. A comparative of gene profiles between mouse and human lung cancers expressing EGFR mutations has not been reported yet. Cancer Cell 2006 9, 421-423DOI: (10.1016/j.ccr.2006.05.014) Copyright © 2006 Elsevier Inc. Terms and Conditions